SCHEMBL1423769

SCHEMBL1423769

COc1cc(Nc2ccn3ncc(-c4ccc(OC)c(OC)c4)c3n2)ccc1Cl

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 2/20 0.63
MAPT P10636 4/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
LMNA P02545 1/20 0.60
POLB P06746 1/20 0.60
FYN P06241 8/20 0.56
MEN1 O00255 1/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
KMT2A Q03164 1/20 0.53
TGFBR2 P37173 2/20 0.47
PIM1 P11309 2/20 0.47
ACVR2A P27037 1/20 0.47
TGFBR1 P36897 1/20 0.47
RET P07949 1/20 0.46
PRKCQ Q04759 1/20 0.43
PIM2 Q9P1W9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1424116 0.86 FYN (0.70) PIK3CGMAPTSMN1; SMN2LMNAPOLB
SCHEMBL4338374 0.86 PIK3CG (0.71) PIK3CGMAPTSMN1; SMN2LMNAPOLB
SCHEMBL4594891 0.86 PIK3CG (0.84) PIK3CGMAPTSMN1; SMN2LMNAPOLB
SCHEMBL4333167 0.85 PIK3CG (0.64) PIK3CGMAPTSMN1; SMN2LMNAPOLB
SCHEMBL4558600 0.84 FYN (0.74) PIK3CGMAPTSMN1; SMN2LMNAPOLB
SCHEMBL4333705 0.82 PIK3CG (0.57) PIK3CGMAPTSMN1; SMN2LMNAPOLB
SCHEMBL4333475 0.82 PIK3CG (0.61) PIK3CGMAPTSMN1; SMN2LMNAPOLB
SCHEMBL4594592 0.80 FYN (0.74) PIK3CGMAPTSMN1; SMN2LMNAPOLB
SCHEMBL14302657 0.80 FYN (0.76) PIK3CGMAPTSMN1; SMN2LMNAPOLB
SCHEMBL4595051 0.79 PIK3CG (0.70) PIK3CGMAPTSMN1; SMN2LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2081933-B1 PYRAZOLOPYRIMIDINES AS PI3K LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2011-03-23 EP claimed
US-20090286779-A1 PYRAZOLOPYRIMIDINES AS LIPID KINASE INHIBITORS NOVARTIS AG 2009-11-19 US claimed
EP-2081933-B1 PYRAZOLOPYRIMIDINES AS PI3K LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2011-03-23 EP disclosed
US-20090286779-A1 PYRAZOLOPYRIMIDINES AS LIPID KINASE INHIBITORS NOVARTIS AG 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286779-A1 PYRAZOLOPYRIMIDINES AS LIPID KINASE INHIBITORS ATR, ATM, CHEK1 PIK3CG 12/4885MAPT 725/4885SMN1; SMN2 2315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.